A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

Abstract Background Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivolumab. Our current purpose was to study the activity and cellular effects o...

Full description

Bibliographic Details
Main Authors: Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia B. Jilaveanu, Harriet M. Kluger
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Molecular Cancer
Subjects:
CD40
Clinical trial
CSF1R
PD-1
Melanoma
Checkpoint inhibition resistance
Online Access:https://doi.org/10.1186/s12943-023-01884-x

Internet

https://doi.org/10.1186/s12943-023-01884-x

Similar Items